Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Earnings Routine +

Victory Square Reports Q1 2026 Financial Results and Provides Portfolio Update

Victory Square Q1 Revenue Hits Guidance Floor as Hydreight Scales and Insu Advances to Phase II

By The Northwire Desk — AI Analysis Jun 02, 2026 · 00:03 VST · 0.78 Victory Square Technologies Inc.
Executive Summary
  • Victory Square Technologies reported Q1 2026 financial results showing revenue of $24.9 million, up from $4.5 million in Q1 2025.
  • Net income reached approximately $3.9 million, with cash and marketable securities increasing to ~$31 million.
  • Hydreight Technologies, the primary revenue driver, expanded its VSDHOne platform to over 12,000 licenses and completed a $15 million financing.
  • Insu Therapeutics received ethics approval to advance its buccal semaglutide delivery program into Phase II studies.
  • Pawsible Ventures launched a $10 million pet-health investment fund and its inaugural cohort of eight companies.
  • Management reiterated a strategic focus on scaling healthcare infrastructure, advancing clinical milestones, and evaluating monetization opportunities.
Material Impact
  • The Q1 revenue of $24.9 million aligns with the lower end of the previously provided $25–28 million guidance, indicating execution is in line with expectations rather than exceeding them.
  • The $3.9 million net income and $31 million cash position demonstrate improved operating leverage and liquidity, supporting the company's ability to fund operations without immediate dilutive financings.
  • Hydreight's $15 million financing and 12,000 license milestone validate the platform's scaling trajectory, but the capital raise introduces minor dilution risk.
  • Insu's Phase II ethics approval is a positive clinical milestone, yet Phase II trials carry inherent execution and regulatory risks that will dictate near-term valuation.
  • The Pawsible Ventures launch is a routine portfolio expansion that adds diversification but does not immediately contribute to consolidated revenue.
  • Overall, the news represents incremental progress that confirms management's forward guidance without introducing unexpected upside or downside surprises.
VST · Price
Company Overview
  • Victory Square Technologies is a diversified holding company focused on scaling infrastructure in complex, high-value markets including digital health, biotech, and pet health.
  • The flagship project is Hydreight Technologies, which operates the VSDHOne platform providing physician coverage, pharmacy relationships, compliance frameworks, and telehealth enablement across all 50 U.S. states.
  • The company also holds stakes in Insu Therapeutics (buccal peptide delivery), Pawsible Ventures (pet-health incubator), SafeTest Diagnósticos (Brazilian diagnostics), and XR Immersive Technologies.
  • Management's strategy centers on building regulated, multi-state healthcare infrastructure and leveraging a venture studio model to incubate and scale portfolio companies.
Read the original news release →

More from Victory Square Technologies Inc.

May 01, 2026 · 00:14

Hydreight Revenue Guidance Confirmed, But Execution Risk Remains on 4x Growth Target

Earnings Apr 23, 2026 · 08:00

Pawsible Ventures Cohort Launch Validates Victory Square Diversification Strategy as Hydreight Scales

Other Mar 09, 2026 · 08:00

Hydreight Announces Normal Course Issuer Bid

Other Feb 18, 2026 · 16:16

Victory Square Provides Corporate Update on Healthcare Infrastructure Strategy and Portfolio Developments

Production / Operations Feb 02, 2026 · 08:00

Hydreight Technologies Issues Fiscal 2026 Revenue Guidance of = $150 Million and Provides Q1 2026 Outlook

Other Dec 18, 2025 · 07:00

Hydreight Exceeds 1.3 Million Product Orders Placed, Surpassing 2025 Operational Targets

Production / Operations